Boni E, Corda L, Franchini D, Chiroli P, Damiani G P, Pini L, Grassi V, Tantucci C
Cattedra di Medicina I, Università di Brescia, Italy.
Thorax. 2002 Jun;57(6):528-32. doi: 10.1136/thorax.57.6.528.
A study was undertaken to investigate whether bronchodilators are associated with less breathlessness at rest and during light exercise in patients with moderate to severe chronic obstructive pulmonary disease (COPD) with resting tidal expiratory flow limitation (EFL; flow limited (FL)) compared with those without EFL (non-flow limited (NFL)).
Twenty subjects (13 men) of mean (SD) age 65 (8) years (range 43-77) suffering from COPD with forced expiratory volume in 1 second (FEV(1)) 47 (18)% predicted were studied before and after inhalation of salbutamol (400 microg). Routine pulmonary function tests were performed in the seated position at rest. EFL was assessed by the negative expiratory pressure (NEP) method and changes in end expiratory lung volume (EELV) were inferred from variations in inspiratory capacity (IC). Dyspnoea was measured using the Borg scale at rest and at the end of a 6 minute steady state exercise test at 33% of the maximal predicted workload.
EFL occurred in 11 patients. Following salbutamol IC did not change in NFL patients but increased by 24% (95% CI 15 to 33) in FL patients (p<0.001). Maximal inspiratory pressure (PImax) improved at EELV from 45 (95% CI 26 to 63) to 55 (95% CI 31 to 79) cm H(2)O (p<0.05) in FL patients after salbutamol but remained unchanged in NFL patients. The workload performed during exercise amounted to 34 (95% CI 27 to 41) and 31 (95% CI 21 to 40) watts (NS) for patients without and with EFL, respectively. After salbutamol, dyspnoea did not change either at rest or during exercise in the NFL patients, but decreased from 0.3 (95% CI -0.1 to 0.8) to 0.1 (95% CI -0.1 to 0.4) at rest (NS) and from 3.7 (95% CI 1.7 to 5.7) to 2.6 (95% CI 1.1 to 4.0) at the end of exercise (p<0.01) in FL patients.
Patients with COPD with EFL may experience less breathlessness after a bronchodilator, at least during light exercise, than those without EFL. This beneficial effect, which is closely related to an increase in IC at rest, occurs even in the absence of a significant improvement in FEV(1) and is associated with a greater PImax.
开展一项研究,旨在调查与无静息潮气呼气流量受限(EFL;流量受限(FL))的中重度慢性阻塞性肺疾病(COPD)患者相比,支气管扩张剂是否与静息及轻度运动时呼吸急促减轻相关。
对20名平均(标准差)年龄65(8)岁(范围43 - 77岁)、患有COPD且第1秒用力呼气量(FEV₁)为预测值47(18)%的受试者(13名男性)在吸入沙丁胺醇(400微克)前后进行研究。静息时坐位进行常规肺功能测试。通过呼气负压(NEP)法评估EFL,并根据吸气量(IC)变化推断呼气末肺容积(EELV)变化。使用Borg量表在静息时以及在最大预测工作量的33%进行6分钟稳态运动测试结束时测量呼吸困难程度。
11名患者存在EFL。吸入沙丁胺醇后,非流量受限(NFL)患者的IC未改变,而流量受限(FL)患者的IC增加了24%(95%可信区间15%至33%)(p<0.001)。FL患者吸入沙丁胺醇后,EELV时的最大吸气压力(PImax)从45(95%可信区间26至63)厘米水柱改善至55(95%可信区间31至79)厘米水柱(p<0.05),而NFL患者保持不变。无EFL和有EFL患者运动时的工作量分别为34(95%可信区间27至41)瓦和31(95%可信区间21至40)瓦(无显著差异)。吸入沙丁胺醇后,NFL患者静息及运动时的呼吸困难均未改变,但FL患者静息时呼吸困难从0.3(95%可信区间 -0.1至0.8)降至0.1(95%可信区间 -0.1至0.4)(无显著差异),运动结束时从3.7(95%可信区间1.7至5.7)降至2.6(95%可信区间1.1至4.0)(p<0.01)。
与无EFL的COPD患者相比,有EFL的COPD患者使用支气管扩张剂后可能至少在轻度运动时呼吸急促减轻。这种有益效果与静息时IC增加密切相关,即使FEV₁无显著改善也会出现,且与更大的PImax相关。